CA2001673C - Pharmaceutical composition containing piroxicam - Google Patents

Pharmaceutical composition containing piroxicam

Info

Publication number
CA2001673C
CA2001673C CA002001673A CA2001673A CA2001673C CA 2001673 C CA2001673 C CA 2001673C CA 002001673 A CA002001673 A CA 002001673A CA 2001673 A CA2001673 A CA 2001673A CA 2001673 C CA2001673 C CA 2001673C
Authority
CA
Canada
Prior art keywords
mass
parts
pharmaceutical composition
process according
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002001673A
Other languages
English (en)
French (fr)
Other versions
CA2001673A1 (en
Inventor
Pal Fekete
Denes Bezzegh
Istvan Simonyi
Biborka Maroshelyi
Katalin Zukovics
Janos Tombor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Egis Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Pharmaceuticals PLC filed Critical Egis Pharmaceuticals PLC
Publication of CA2001673A1 publication Critical patent/CA2001673A1/en
Application granted granted Critical
Publication of CA2001673C publication Critical patent/CA2001673C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002001673A 1988-10-28 1989-10-27 Pharmaceutical composition containing piroxicam Expired - Fee Related CA2001673C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU885621A HU200926B (en) 1988-10-28 1988-10-28 Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules
HU5621/88 1988-10-28

Publications (2)

Publication Number Publication Date
CA2001673A1 CA2001673A1 (en) 1990-04-28
CA2001673C true CA2001673C (en) 1996-08-27

Family

ID=10970484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002001673A Expired - Fee Related CA2001673C (en) 1988-10-28 1989-10-27 Pharmaceutical composition containing piroxicam

Country Status (9)

Country Link
JP (1) JPH02172918A (it)
AT (1) AT399277B (it)
CA (1) CA2001673C (it)
DE (1) DE3936112C2 (it)
FR (1) FR2638357B1 (it)
GB (1) GB2224207B (it)
HU (1) HU200926B (it)
IL (1) IL92138A (it)
IT (1) IT1239542B (it)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
JP2964195B2 (ja) * 1992-04-28 1999-10-18 エスエス製薬株式会社 ピロキシカム錠及びその製造法
DE19603402A1 (de) * 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
AU733032C (en) * 1996-06-14 2002-01-03 Kyowa Hakko Kirin Co., Ltd. Intraorally rapidly disintegrable tablet
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
JP4568426B2 (ja) * 1998-04-08 2010-10-27 協和発酵キリン株式会社 錠剤の製造方法及び錠剤
JP2000095674A (ja) 1998-09-22 2000-04-04 Sato Pharmaceutical Co Ltd 口腔内崩壊時間短縮化錠剤の製造方法及び装置
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
EP1574215B1 (en) * 2002-12-16 2015-07-15 Kissei Pharmaceutical Co., Ltd. Solid drug for oral use
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CN101232905B (zh) * 2005-07-25 2013-01-09 大塚制药株式会社 一种用于测量嘧啶代谢能力的口服制剂
CN102958515A (zh) 2009-12-02 2013-03-06 阿普塔利斯制药有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
EP2887066B1 (en) 2012-08-20 2020-08-05 Otsuka Pharmaceutical Co., Ltd. Composition for use in a method for measuring carbohydrate metabolism ability
CN105051533B (zh) 2013-03-15 2019-03-26 大塚制药株式会社 基于脂肪酸燃烧的测定胰岛素抵抗性的方法及用于该方法的组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591584A (en) * 1968-08-27 1971-07-06 Pfizer Benzothiazine dioxides
GB1308533A (en) * 1969-06-02 1973-02-21 Pfizer Benzothiazine dioxides as anti-thombotic agents
JPS55129221A (en) * 1979-03-29 1980-10-06 Kaken Pharmaceut Co Ltd Preparation of oral preparation containing hardly soluble medicine
US4350689A (en) * 1980-02-15 1982-09-21 American Cyanamid Company Combinations of agents which give enhanced anti-inflammatory activity
US4434164A (en) * 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
RO88420A (ro) * 1983-04-25 1986-01-30 Pfizer Inc,Us Procedeu pentru prepararea unor saruri bazice de piroxican depuse pe suporturi farmaceutice
DE3419128A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Dihydropyridinpraeparate und verfahren zu ihrer herstellung
CH663899A5 (fr) * 1985-03-20 1988-01-29 Nestle Sa Procede pour la preparation d'une composition a base d'un principe actif de faible hydrosolubilite finement divise.
ES545221A0 (es) * 1985-07-02 1986-01-01 Ferrer Int Procedimiento de obtencion de particulas de 4-hidroxi-2-me- til-n-2-piridil-2h-1,2-benzotiazina-3-carboxamida-1,1-dioxi-do(piroxicam) recubiertas

Also Published As

Publication number Publication date
FR2638357A1 (fr) 1990-05-04
GB8924286D0 (en) 1989-12-13
HUT51143A (en) 1990-04-28
ATA247489A (de) 1994-09-15
CA2001673A1 (en) 1990-04-28
FR2638357B1 (fr) 1993-10-22
IT1239542B (it) 1993-11-05
IT8922164A1 (it) 1991-04-27
GB2224207B (en) 1992-06-10
IL92138A0 (en) 1990-07-12
HU200926B (en) 1990-09-28
DE3936112A1 (de) 1990-05-31
JPH02172918A (ja) 1990-07-04
IL92138A (en) 1994-08-26
DE3936112C2 (de) 1999-02-18
AT399277B (de) 1995-04-25
GB2224207A (en) 1990-05-02
IT8922164A0 (it) 1989-10-27

Similar Documents

Publication Publication Date Title
CA2001673C (en) Pharmaceutical composition containing piroxicam
RU2181590C2 (ru) Фармацевтические композиции, содержащие ирбесартан
AU684522B2 (en) Pharmaceutical thermal infusion process
US6143328A (en) Sustained release compositions and a method of preparing pharmaceutical compositions
US5824344A (en) Pharmaceutical thermal infusion granules
JP4787446B2 (ja) グリブリド組成物
TWI415633B (zh) Solid preparations containing enteric solid dispersions
CA2644905A1 (en) Ezetimibe compositions
EP0365480B1 (en) Dispersible formulation
SK285706B6 (sk) Lisovaná tabletová kompozícia, spôsob jej prípravy a jej použitie
Bolhuis et al. Evaluation of anhydrous α-lactose, a new excipient in direct compression
IE64659B1 (en) Pimobendan compositions
GB2284760A (en) Sustained release morphine compositions
JPS5927820A (ja) スロクチジルを含有する徐放性製品
JP3224379B1 (ja) 8−クロロ−6,11−ジヒドロ−11−(4−ピペリジリデン)−5H−ベンゾ[5,6]シクロヘプタ[1,2−b]ピリジンの経口用組成物
US6365196B1 (en) Controlled release solid dosage forms of lithium carbonate
US5827537A (en) Pharmaceutical thermal infusion process
WO1997033571A1 (fr) Preparation d'ecadotril a microdispersion et liberation rapides
CA1165242A (en) Compressed and formed alkaline component suitable for use in buffered acetylsalicylic acid product
SK279927B6 (sk) Orálne pevné farmaceutické prípravky obsahujúce ge
NO318575B1 (no) Stabile sammensetninger som omfatter levosimendan og alginsyre
US6056974A (en) Rapid-release S1452 tablets
JPH10226644A (ja) 医薬組成物
JP2864737B2 (ja) 徐放性製剤用基剤並びに徐放性製剤及び該製剤の製造方法
WO2023139312A1 (en) Pharmaceutical composition of a cyp11a1 inhibitor

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed